Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TaiGen Biopharmaceuticals Holdings's quarterly market cap
declined
from Jun. 2025 (NT$6,618.5 Mil) to Sep. 2025 (NT$6,199.7 Mil) but then
increased
from Sep. 2025 (NT$6,199.7 Mil) to Dec. 2025 (NT$9,538.6 Mil).
TaiGen Biopharmaceuticals Holdings's annual market cap
declined
from Dec. 2023 (NT$10,911.2 Mil) to Dec. 2024 (NT$8,219.3 Mil) but then
increased
from Dec. 2024 (NT$8,219.3 Mil) to Dec. 2025 (NT$9,538.6 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. TaiGen Biopharmaceuticals Holdings's Enterprise Value for Today is NT$5,336.4 Mil.
TaiGen Biopharmaceuticals Holdings (ROCO:4157) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
TaiGen Biopharmaceuticals Holdings Market Cap Related Terms
TaiGen Biopharmaceuticals Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TaiGen Biopharmaceuticals Holdings Market Cap Chart
ROCO:4157 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, TaiGen Biopharmaceuticals Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiGen Biopharmaceuticals Holdings Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiGen Biopharmaceuticals Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where TaiGen Biopharmaceuticals Holdings's Market Cap falls into.
TaiGen Biopharmaceuticals Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TaiGen Biopharmaceuticals Holdings (ROCO:4157) has a Market Cap of NT$6,314.0 Mil as of Jul. 16, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. According to the industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #604 out of 1423 companies in the Biotechnology industry, placing it in the top 42.4%.
Is TaiGen Biopharmaceuticals Holdings' Market Cap too high?
TaiGen Biopharmaceuticals Holdings' current Market Cap is NT$6,314.0 Mil. Based on the distribution chart, TaiGen Biopharmaceuticals Holdings ranks #604 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, TaiGen Biopharmaceuticals Holdings has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiGen Biopharmaceuticals Holdings' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #604 out of 1423 companies for Market Cap. This puts TaiGen Biopharmaceuticals Holdings in the upper half of its industry. The industry median Market Cap is 117.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.38, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 117.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiGen Biopharmaceuticals Holdings's current Market Cap is NT$6,314.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiGen Biopharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings (ROCO:4157) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$34.16, compared to a current price of NT$8.87 — trading 74% below its estimated fair value. The current Market Cap is NT$6,314.0 Mil. TaiGen Biopharmaceuticals Holdings' overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For TaiGen Biopharmaceuticals Holdings (ROCO:4157), the current Market Cap is NT$6,314.0 Mil as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiGen Biopharmaceuticals Holdings (ROCO:4157) Overvalued in 2026?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings stock appears to be undervalued.
The current stock price of NT$8.87 is trading 74% below its estimated GF Value™ of NT$34.16.
GuruFocus considers TaiGen Biopharmaceuticals Holdings to be Significantly Undervalued.
Key valuation signals for ROCO:4157:
Market Cap: NT$6,314.0 Mil
GF Value™: NT$34.16 vs. price of NT$8.87 (74% below fair value)
No single metric tells the full story. See the ROCO:4157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiGen Biopharmaceuticals Holdings Business Description
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
59GF Score
Get the complete analysis for ROCO:4157
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4157 has been successfully added to your 
